„First Line“
Suchergebnisse
3.416 Treffer
-
Early metabolic response in sequential FDG-PET/CT under cetuximab is a predictive marker for clinical response in first-line metastatic colorectal cancer patients: results of the phase II REMOTUX trial
-
TG4010 immunotherapy plus chemotherapy as first-line treatment of advanced non small cell lung cancer (NSCLC): Phase IIb results of the TIME trial
-
Management of Adult Patients with Newly Diagnosed or Relapsed Primary Immune Thrombocytopenia in Eastern Austria
-
Venous thrombotic events and impact on outcomes in patients treated with first-line single-agent pembrolizumab in PD-L1 ≥ 50% advanced non small cell lung cancer
-
A phase I/II study of 4′-O-tetrahydropyranyl-doxorubicin, 5-fluorouracil, and high-dose leucovorin as first-line therapy in advanced breast cancer patients
-
Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients
-
Systemic Treatment of Advanced Unresectable Hepatocellular Carcinoma after First-Line Therapy: Expert Recommendations from Hong Kong, Singapore, and Taiwan
-
Non-invasive ventilatory support and high-flow nasal oxygen as first-line treatment of acute hypoxemic respiratory failure and ARDS
-
Electrochemotherapy with Bleomycin Enhances Radiosensitivity of Uveal Melanomas – First In Vitro Results in 3D Cultures of Primary Uveal Melanoma Cell Lines
-
Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry
-
MiR-502 is the first reported miRNA simultaneously targeting two components of the classical non-homologous end joining (C-NHEJ) in pancreatic cell lines.
-
Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line
-
Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study group)
-
A prognostic model for survival of patients with metastatic upper tract urothelial carcinoma with first-line systemic therapy
-
Peripheral inflammatory factors as prognostic predictors for first-line PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer
-
Attrition in the First Three Therapy Lines in Patients with Advanced Breast Cancer in the German Real-World PRAEGNANT Registry
-
First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations
-
First‐line nab‐paclitaxel plus carboplatin for patients with advanced non‐small cell lung cancer: final results of the NEPTUN study
-
Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models
-
FDG-PET biomarkers associated with long-term benefit from first-line immunotherapy in patients with advanced non-small cell lung cancer